Walvax BioTech (SHE:300142) — Market Cap & Net Worth
Market Cap & Net Worth: Walvax BioTech (300142)
Walvax BioTech (SHE:300142) has a market capitalization of $3.04 Billion (CN¥20.81 Billion) as of September 16, 2026. Listed on the SHE stock exchange, this China-based company holds position #4877 globally and #815 in its home market, demonstrating a -0.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Walvax BioTech's stock price CN¥13.01 by its total outstanding shares 1599348541 (1.60 Billion). Also see Walvax BioTech balance sheet assets for a full breakdown of the balance sheet.
Walvax BioTech Market Cap History: 2015 to 2026
Walvax BioTech's market capitalization history from 2015 to 2026. Data shows change from $3.07 Billion to $3.04 Billion (-1.97% CAGR). Also see 300142 operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Walvax BioTech is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ChiNext
CNT
|
$1.14 Trillion | 0.27% | #64 of 100 |
Weight: Walvax BioTech's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Walvax BioTech Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Walvax BioTech's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Walvax BioTech share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.06x
Walvax BioTech's market cap is 1.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
14.37x
Walvax BioTech's market cap is 14.37 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.54 Billion | $591.00 Million | $70.46 Million | 4.30x | 36.07x |
| 2017 | $4.25 Billion | $668.26 Million | -$537.14 Million | 6.37x | N/A |
| 2018 | $4.45 Billion | $874.32 Million | $1.05 Billion | 5.09x | 4.26x |
| 2019 | $7.57 Billion | $1.12 Billion | $141.97 Million | 6.75x | 53.33x |
| 2020 | $9.00 Billion | $2.94 Billion | $1.00 Billion | 3.06x | 8.97x |
| 2021 | $13.13 Billion | $3.46 Billion | $427.75 Million | 3.79x | 30.70x |
| 2022 | $9.40 Billion | $5.09 Billion | $728.65 Million | 1.85x | 12.89x |
| 2023 | $5.50 Billion | $4.11 Billion | $419.39 Million | 1.34x | 13.11x |
| 2024 | $2.83 Billion | $2.82 Billion | $142.16 Million | 1.00x | 19.89x |
| 2025 | $2.55 Billion | $2.41 Billion | $177.74 Million | 1.06x | 14.37x |
Competitor Companies of 300142 by Market Capitalization
Companies near Walvax BioTech in the global market cap rankings as of September 16, 2026. Review 300142 goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Walvax BioTech by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Walvax BioTech Historical Marketcap From 2015 to 2026
Between 2015 and today, Walvax BioTech's market cap moved from $3.07 Billion to $ 3.04 Billion, with a yearly change of -1.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.04 Billion | +19.25% |
| 2025 | CN¥2.55 Billion | -9.69% |
| 2024 | CN¥2.83 Billion | -48.58% |
| 2023 | CN¥5.50 Billion | -41.48% |
| 2022 | CN¥9.40 Billion | -28.45% |
| 2021 | CN¥13.13 Billion | +45.85% |
| 2020 | CN¥9.00 Billion | +18.91% |
| 2019 | CN¥7.57 Billion | +70.03% |
| 2018 | CN¥4.45 Billion | +4.66% |
| 2017 | CN¥4.25 Billion | +67.43% |
| 2016 | CN¥2.54 Billion | -17.30% |
| 2015 | CN¥3.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Walvax BioTech was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.04 Billion USD |
| MoneyControl | $3.04 Billion USD |
| MarketWatch | $3.04 Billion USD |
| marketcap.company | $3.04 Billion USD |
| Reuters | $3.04 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Walvax BioTech
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, grou… Read more